ReviewInternational journal of urology : official journal of the Japanese Urological Association2025
Frontiers of Ultrasound Technology in Prostate Cancer Treatment.
Review in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Focal therapy is a minimally invasive alternative treatment for localized prostate cancer (PC) aiming to achieve oncological control while preserving urinary and sexual functions. High-intensity focused ultrasound (HIFU) and high-intensity directional ultrasound (HIDU) enable precise prostate ablation guided by real-time transrectal ultrasound or magnetic resonance imaging (MRI) fusion imaging. This review evaluates the current status and prospects of ultrasound technology in the treatment of PC. HIFU provides precise tumor ablation with minimal damage to the surrounding tissues, whereas HIDU allows MRI-guided transurethral treatment with real-time thermometry. Clinical studies have reported favorable biochemical recurrence-free survival and functional outcomes. In Japan, a multi-institutional prospective study on focal therapy using HIFU has been approved as an advanced medical technology by the Minister of Health, Labor, and Welfare. This study compared the oncological and functional outcomes of HIFU-based focal therapy and radical prostatectomy in pair-matched patients to evaluate the effectiveness of HIFU in treating localized PC. HIFU induces immunogenic cell death, releases tumor-associated antigens, and reduces immunosuppressive cells. Low-intensity focused ultrasound enhances tumor immunogenicity by promoting heat shock protein expression and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.